Drug Trial News

RSS

New stem cell therapy significantly improves outcomes in patients with severe heart failure

A new stem cell therapy significantly improved long-term health outcomes in patients with severe and end-stage heart failure in a study presented at the American College of Cardiology's 65th Annual Scientific Session.

5 Apr 2016

Investigational drug provides no improved protection to patients with contrast-induced acute kidney injury

Patients treated with CMX-2043--an investigational drug that has previously shown some ability to protect heart muscle from damage during stenting--saw no improved protection in their kidneys compared to placebo, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.

5 Apr 2016

Evolocumab could be more effective than ezetimibe in lowering cholesterol in statin-intolerant patients

In the first major trial of its kind, Cleveland Clinic researchers used a blinded rechallenge with atorvastatin or placebo to objectively confirm the presence of muscle-related symptoms in patients with a history of intolerance to multiple statins and found that evolocumab (a PCSK9 inhibitor) was a more effective option to lower cholesterol than ezetimibe in these patients.

4 Apr 2016

Researchers compare lipid-lowering efficacy for two nonstatin therapies in statin-intolerant patients

Steven E. Nissen, M.D., of the Cleveland Clinic, and colleagues identified patients with muscle-related adverse effects from statins and compared lipid-lowering efficacy for two nonstatin therapies, ezetimibe and evolocumab. The study was published online by JAMA, and is being released to coincide with its presentation at the American College of Cardiology's 65th Annual Scientific Session & Expo.

4 Apr 2016

Investigational drug abaloparatide-SC may help increase bone mineral density in postmenopausal women

The investigational drug abaloparatide-SC (subcutaneous) may help increase bone mineral density in postmenopausal women and reduce their risk of fracture, new industry-sponsored research suggests. The results of the subgroup analysis within the ACTIVE clinical trial will be presented Friday, April 1, at ENDO 2016, the annual meeting of the Endocrine Society in Boston.

4 Apr 2016

Cholesterol drug evacetrapib fails to reduce risk of cardiovascular events

Despite lowering low-density lipoprotein (LDL), known as "bad" cholesterol, while markedly increasing levels of high-density lipoprotein (HDL), or "good" cholesterol, a large clinical trial to investigate the cholesterol drug evacetrapib was discontinued early after a preliminary analysis showed it did not reduce rates of major adverse cardiovascular events, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.

4 Apr 2016

Plitidepsin in combination with dexamethasone shows top-line results in Phase III multiple myeloma trial

PharmaMar today announced positive top-line results of its Phase III clinical trial -ADMYRE- with Aplidin (plitidepsin) in combination with dexamethasone versus dexamethasone alone in patients with relapsed/refractory multiple myeloma (MM).

2 Apr 2016

Baricitinib drug shows significant success in treatment of rheumatoid arthritis

In a clinical phase-3-study, an international research cooperation of MedUni Vienna and Stanford University has achieved significant success with the drug Baricitinib for the treatment of rheumatoid arthritis. The test persons exhibited significantly less symptoms of the disorder. The results are now published in the top scientific journal "New England Journal of Medicine".

31 Mar 2016

Naltrexone injections could reduce risk of relapse among opioid dependent individuals

In a multicenter, randomized clinical trial, ex-prisoners who received six monthly injections of naltrexone--a long-acting medication that blocks opioid receptors in the brain--were significantly less likely to resume opioid use than those who received counseling and referrals to community treatment centers without naltrexone.

31 Mar 2016

BodyGuard wearable patch product shows superiority to common NSAID treatments in restoring joint function

Perth skin science technology company OBJ Limited is set to revolutionise treatment of joint injuries and osteoarthritis after its BodyGuard wearable patch product proved its superiority to the world-leading non-steroidal anti-inflammatory drug product Voltaren.

31 Mar 2016

Fatty acid supplement can help reduce early preterm births

Cupid was obviously a full-term baby. It's fitting then that a researcher named Valentine and her colleagues will oversee a new multicenter National Institutes of Health study to determine whether an over the counter fatty acid supplement, called DHA (Docosahexaenoic acid, an omega-3 fatty acid), can assist with reducing early preterm births.

24 Mar 2016

UC San Diego Health participates in nationwide clinical study on hemophilia B gene therapy

The Hemophilia and Thrombosis Treatment Center at UC San Diego Health has joined a nationwide clinical trial testing a potential gene therapy that may one day provide a better and long-lasting treatment for people with hemophilia B.

23 Mar 2016

GEMINI LTS study: Patients with active ulcerative colitis report clinical improvements with vedolizumab treatment

Takeda Pharmaceutical Company Limited, (“Takeda”) today announced that the interim findings from the GEMINI Long-Term Safety (LTS) study were presented during the 2016 European Crohn's and Colitis Organisation (ECCO) Annual Scientific Meeting in Amsterdam, The Netherlands.

22 Mar 2016

Simple TB screening and isoniazid can be effective for HIV patients at risk for TB

The number one killer of HIV patients in resource-limited areas, including parts of Africa and India, is tuberculosis (TB), underscoring the need for optimal treatments and effective strategies to address this deadly co-infection. But TB is harder to detect in HIV-infected patients and diagnostic test results take time, so many healthcare providers prescribe multi-drug TB treatments as a precaution.

20 Mar 2016

Antibiotic treatment for mild appendicitis does not increase risk for complications

Using antibiotics as the primary treatment for mild appendicitis does not increase the risk for complications at least in the first year. But other considerations must also be taken into account, say researchers.

19 Mar 2016

Paracetamol does not meet minimum standard of clinical effectiveness in osteoarthritis patients

In a large-scale analysis of pain-relief medication for osteoarthritis, researchers found that paracetamol does not meet the minimum standard of clinical effectiveness in reducing pain or improving physical function in patients with knee and hip osteoarthritis.

18 Mar 2016

Findings could be final puzzle piece in developing effective dengue vaccine

In a small clinical trial led by the Johns Hopkins Bloomberg School of Public Health, researchers say that a promising single-dose dengue vaccine, developed by scientists at the National Institutes of Health, was 100 percent effective in preventing human volunteers from contracting the virus, the most prevalent mosquito-borne virus in the world.

18 Mar 2016

Clinical study finds no added benefit of using four TB drugs to save people with advanced HIV/AIDS

In a report on the so-called REMEMBER (Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment) study -- a 10-nation, randomized clinical trial of adult outpatients -- investigators concluded that there was no added benefit of using four drugs for TB over just using one drug, isoniazid, to save lives in people with advanced HIV/AIDS.

18 Mar 2016

MUSC surgeon awarded $3.8 million grant to evaluate transplant drug

Seldom can one say $3.8 million is just the tip of the iceberg, but a newly awarded grant from Gilead Sciences, Inc. is just that. MUSC transplant surgeon Kenneth Chavin, M.D., Ph.D., says the true value of the multi-center drug trial is closer to $26 million, including $22 million in free drugs provided by the pharmaceutical company.

17 Mar 2016

Halozyme Therapeutics doses first patient in Halo-301 | Pancreatic study

Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, today announced the first patient has been dosed in its Halo-301 | Pancreatic study, a Phase 3 clinical trial in previously untreated metastatic pancreatic cancer patients.

16 Mar 2016

Drug Trial News

New stem cell therapy significantly improves outcomes in patients with severe heart failure

Investigational drug provides no improved protection to patients with contrast-induced acute kidney injury

Evolocumab could be more effective than ezetimibe in lowering cholesterol in statin-intolerant patients

Researchers compare lipid-lowering efficacy for two nonstatin therapies in statin-intolerant patients

Investigational drug abaloparatide-SC may help increase bone mineral density in postmenopausal women

Cholesterol drug evacetrapib fails to reduce risk of cardiovascular events

Plitidepsin in combination with dexamethasone shows top-line results in Phase III multiple myeloma trial

Baricitinib drug shows significant success in treatment of rheumatoid arthritis

Naltrexone injections could reduce risk of relapse among opioid dependent individuals

BodyGuard wearable patch product shows superiority to common NSAID treatments in restoring joint function

Fatty acid supplement can help reduce early preterm births

UC San Diego Health participates in nationwide clinical study on hemophilia B gene therapy

GEMINI LTS study: Patients with active ulcerative colitis report clinical improvements with vedolizumab treatment

Simple TB screening and isoniazid can be effective for HIV patients at risk for TB

Antibiotic treatment for mild appendicitis does not increase risk for complications

Paracetamol does not meet minimum standard of clinical effectiveness in osteoarthritis patients

Findings could be final puzzle piece in developing effective dengue vaccine

Clinical study finds no added benefit of using four TB drugs to save people with advanced HIV/AIDS

MUSC surgeon awarded $3.8 million grant to evaluate transplant drug

Halozyme Therapeutics doses first patient in Halo-301 | Pancreatic study

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Latest News